Flagship Pioneering, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Flagship Pioneering, LLC reported 5 stock positions worth $334.2 million. Its top holding was Moderna (MRNA) at 57.6% of the portfolio, followed by Foghorn Therapeutics (FHTX, 17.9%) and Sana Biotechnology (SANA, 12.2%). Compared with Q3 2024, it sold out of 1. The biggest sale was an exit from Syros Pharmaceuticals (SYRS).
- Most Recent 13F
- Q2 2026
- Location
- CAMBRIDGE, MA
- CIK
- 0001400240
- Portfolio Value
- $334.2M (Q4 2024)
- SEC Filing
- 0000950123-25-002708 ↗ filed Feb 14, 2025
Holdings Value
Holdings 5 stocks · $334.2M
| MRNA Moderna Inc. | 57.63% | 4,632,149 | $192.6M | No change |
| FHTX Foghorn Therapeutics Inc. | 17.90% | 12,674,120 | $59.8M | No change |
| SANA Sana Biotechnology Inc. | 12.19% | 25,001,856 | $40.8M | No change |
| OMGAQ Omega Therapeutics Inc. | 6.52% | 29,225,579 | $21.8M | No change |
| MCRB Seres Therapeutics Inc. | 5.76% | 23,117,045 | $19.3M | No change |
Portfolio Sells Q3 2024 → Q4 2024
| SYRS Syros Pharmaceuticals Inc. | Sold out | 0.00% | −0.47 |
Portfolio Buys Q3 2024 → Q4 2024
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $1.5B | GENB, MRNA, SANA, FHTX, MCRB |
| Q1 2026 | 5 | $1.2B | GENB, MRNA, SANA, FHTX, MCRB |
| Q4 2025 | 4 | $324.0M | MRNA, SANA, FHTX, MCRB |
| Q3 2025 | 4 | $292.6M | MRNA, SANA, FHTX, MCRB |
| Q2 2025 | 4 | $268.5M | MRNA, SANA, FHTX, MCRB |
| Q1 2025 | 4 | $235.8M | MRNA, FHTX, SANA, MCRB |
| Q4 2024 | 5 | $334.2M | MRNA, FHTX, SANA, OMGAQ, MCRB |
| Q3 2024 | 6 | $591.9M | MRNA, FHTX, SANA, OMGAQ, MCRB |
| Q2 2024 | 6 | $843.4M | MRNA, SANA, FHTX, OMGAQ, MCRB |
| Q1 2024 | 7 | $1.5B | MRNA, SANA, OMGAQ, FHTX, DNLI |